MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Vaccine
Päätekijät: Coleman, Christopher M., Venkataraman, Thiagarajan, Liu, Ye V., Glenn, Gregory M., Smith, Gale E., Flyer, David C., Frieman, Matthew B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier Ltd. 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423355/
https://ncbi.nlm.nih.gov/pubmed/28237499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2017.02.012
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia